Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in COPD: A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS.

Am J Respir Crit Care Med. 2018 Aug 10. doi: 10.1164/rccm.201802-0286OC. [Epub ahead of print]

PMID:
30095981
2.

Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy.

Rooks DS, Laurent D, Praestgaard J, Rasmussen S, Bartlett M, Tankó LB.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):727-734. doi: 10.1002/jcsm.12205. Epub 2017 Sep 14.

3.

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.

Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R.

J Am Geriatr Soc. 2017 Sep;65(9):1988-1995. doi: 10.1111/jgs.14927. Epub 2017 Jun 27.

PMID:
28653345
4.

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.

Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, Sunkara G, Kovacs SJ, Villano S, Tanaka SK.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7431-7435. Print 2016 Dec.

5.

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.

Barve A, Kovacs SJ, Ke J, Crabbe R, Grosgurin P, Menetrey A, Nicolas-Métral V, Dabovic K, Dole K, Zhang J, Praestgaard J, Sunkara G, Stein D.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):25-32. doi: 10.1002/cpdd.114. Epub 2014 May 26.

PMID:
27128001
6.

mTOR inhibition improves immune function in the elderly.

Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB.

Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892.

PMID:
25540326
7.

Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.

Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P.

Antimicrob Agents Chemother. 2015 Mar;59(3):1435-40. doi: 10.1128/AAC.04251-14. Epub 2014 Dec 22.

8.

Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.

Bhansali SG, Mullane K, Ting LS, Leeds JA, Dabovic K, Praestgaard J, Pertel P.

Antimicrob Agents Chemother. 2015 Mar;59(3):1441-5. doi: 10.1128/AAC.04252-14. Epub 2014 Dec 22.

9.

Treatment of sporadic inclusion body myositis with bimagrumab.

Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA.

Neurology. 2014 Dec 9;83(24):2239-46. doi: 10.1212/WNL.0000000000001070. Epub 2014 Nov 7.

10.

Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.

Colvin RA, Tanwandee T, Piratvisuth T, Thongsawat S, Hui AJ, Zhang H, Ren H, Chen PJ, Chuang WL, Sobhonslidsuk A, Li R, Qi Y, Praestgaard J, Han Y, Xu J, Stein DS; ABF656A2206 Study Group.

J Gastroenterol Hepatol. 2015 Jan;30(1):184-91. doi: 10.1111/jgh.12671.

PMID:
24995515
11.

Donor hemodynamic profile presages graft survival in donation after cardiac death liver transplantation.

Abt PL, Praestgaard J, West S, Hasz R.

Liver Transpl. 2014 Feb;20(2):165-72. doi: 10.1002/lt.23777. Epub 2013 Dec 12.

12.

Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.

Stein DS, Ke J, Uy G, Bosheva M, Qi Y, Praestgaard J; LDT600A2104 Study Team.

Antimicrob Agents Chemother. 2013 Sep;57(9):4128-33. doi: 10.1128/AAC.00117-13. Epub 2013 Jun 17.

13.

A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.

Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P.

Antimicrob Agents Chemother. 2012 Nov;56(11):5946-51. doi: 10.1128/AAC.00867-12. Epub 2012 Sep 10.

14.

Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D.

Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. doi: 10.1128/AAC.06355-11. Epub 2012 May 29.

15.

A comparative study of hydrolysis and transglycosylation activities of fungal β-glucosidases.

Bohlin C, Praestgaard E, Baumann MJ, Borch K, Praestgaard J, Monrad RN, Westh P.

Appl Microbiol Biotechnol. 2013 Jan;97(1):159-69. doi: 10.1007/s00253-012-3875-9. Epub 2012 Feb 7.

PMID:
22311644
16.

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.

Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J, Huang M, Praestgaard J, Serra D, Evans TG.

Antiviral Res. 2011 Mar;89(3):238-45. doi: 10.1016/j.antiviral.2011.01.003. Epub 2011 Jan 19.

PMID:
21255610
17.

Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers.

Serra DB, Sun H, Karwowska S, Praestgaard J, Halabi A, Stein DS.

Antimicrob Agents Chemother. 2011 Feb;55(2):473-7. doi: 10.1128/AAC.00626-10. Epub 2010 Nov 22.

18.

Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C.

Balan V, Aravind L, Grill DE, Therneau TM, Sulkowski MS, Nelson DR, Praestgaard J, Rosati M, Birse CE, Moore PA, Mani Subramanian G.

Hepatol Res. 2006 Dec;36(4):277-87. Epub 2006 Oct 9.

PMID:
17030011
19.

Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles.

Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG.

Toxicol Appl Pharmacol. 2001 Aug 15;175(1):28-42.

PMID:
11509024
20.

Privileged molecules for protein binding identified from NMR-based screening.

Hajduk PJ, Bures M, Praestgaard J, Fesik SW.

J Med Chem. 2000 Sep 7;43(18):3443-7.

PMID:
10978192
21.

Evaluation of the extent of nonlinearity in reportable range studies.

Kroll MH, Praestgaard J, Michaliszyn E, Styer PE.

Arch Pathol Lab Med. 2000 Sep;124(9):1331-8.

PMID:
10975932
22.

A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys.

Cunningham MT, Praestgaard J, Styer PE, Brandt JT, Fairweather RB, Laposata M, Olson JD, Sosolik RC, Triplett DA.

Arch Pathol Lab Med. 1999 Mar;123(3):199-205.

PMID:
10086507

Supplemental Content

Loading ...
Support Center